HBM Holdings Limited
HKSE: 2142.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jingsong Wang
- Employees
- 183
- Headquarters
- Shanghai, China
- IPO year
- 2020
- Market cap
- HK$11.1B
- Website
- https://www.harbourbiomed.com
Loading 2142…
Loading profile data…Frequently asked questions about 2142
What does HBM Holdings Limited (2142.HK) do?
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfa...
Where does 2142.HK trade?
HBM Holdings Limited (2142.HK) trades on the Hong Kong Stock Exchange.
What sector is 2142.HK in?
HBM Holdings Limited (2142.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of HBM Holdings Limited?
Jingsong Wang is the chief executive officer of HBM Holdings Limited (2142.HK).
Where is HBM Holdings Limited headquartered?
HBM Holdings Limited is headquartered in China.
Does 2142.HK pay a dividend?
HBM Holdings Limited (2142.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2142.HK go public?
HBM Holdings Limited (2142.HK) completed its initial public offering in 2020.